Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Discover how metabolic ketogenic therapy differs from the popular diet trend and its potential benefits for bipolar disorder.